"Noxopharm has identified a third drug candidate as a potential acquisition. This asset is owned by a private drug development company, Cardio Therapeutics Pty Ltd ACN 167 825 201 (Cardio), a company owned by Altnia Holdings Pty Ltd ACN 133 349 238 as trustee for the I. Dixon Family Trust (Altnia). Altnia is controlled by Dr. Ian Dixon, a non-executive director of Noxopharm. This asset is a small molecule drug designed to lower LDL cholesterol levels through inhibition of the PCSK9 protein, potentially offering significant advantages compared to current therapies. This drug candidate is also undergoing pre-clinical development." (25 September 2017)
NOX Price at posting:
38.0¢ Sentiment: None Disclosure: Not Held
